The key lies within the mitochondria of tumor cells, where high levels of reactive oxygen species (ROS) accumulate as a result of rapid metabolism. Tumors protect themselves by producing antioxidant enzymes, including peroxiredoxin 3 (PRX3), which detoxifies harmful molecules to maintain cellular survival. Contrary to prior attempts aiming to increase antioxidants to slow tumor growth, the UVM team, led by Professor Brian Cunniff and postdoctoral scientist Victoria Gibson, chose to inhibit PRX3, saturate the tumor with oxidative stress, and induce cell death.

The drug, RSO-021, developed in collaboration with RS Oncology LLC, uses thiostrepton, a naturally occurring antibiotic, to disable PRX3. This inhibition leads to an accumulation of hydrogen peroxide in the mitochondria, triggering apoptosis selectively in cancer cells due to their elevated ROS production. Laboratory experiments demonstrated that removing PRX3 crippled mitochondrial function, arrested tumor growth, and prevented tumor formation in animal models, without adverse effects in healthy mice—addressing common concerns about targeting mitochondria.

A phase one clinical trial conducted in the UK enrolled patients with relapsed mesothelioma, delivering the drug directly into the chest cavity via a catheter. This local administration concentrates the therapy at the tumor site while limiting systemic toxicity. The trial met its safety endpoints, showed disease stabilization in 67% of patients, and, notably, indicated improved overall survival compared to existing treatments—a promising sign of clinical efficacy.

Beyond its cytotoxic effects, preliminary data suggest RSO-021 may also activate the immune system, potentially enhancing the body’s own response to tumors. These dual effects mark a significant advance in cancer therapeutics, blending targeted molecular attack with immunomodulation.

The success of the phase one trial has propelled the research into phase two, with results anticipated later this year. Meanwhile, efforts are underway to develop second-generation PRX3 inhibitors with improved solubility and oral bioavailability, facilitating broader applications across other cancer types. Victoria Gibson continues her work at UVM, expanding investigations into peritoneal and gastrointestinal malignancies.

This paradigm-shifting approach offers a beacon of hope for mesothelioma patients and exemplifies how challenging prevailing cancer treatment dogma can unlock new avenues for therapy with potential widespread impact.

Subject of Research: People
Article Title: Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer
News Publication Date: 14-Jul-2026
Web References: http://dx.doi.org/10.1038/s41467-026-75153-y
Image Credits: Joshua Brown/UVM
Keywords: Mesothelioma, PRX3, reactive oxygen species, thiostrepton, mitochondria, cancer therapy, clinical trial, oxidative stress, immunomodulation

Triple-negative breast cancer is known for its lack of three key receptors: estrogen, progesterone, and the HER2 protein. This deficiency renders traditional treatment options like hormone therapy and targeted HER2 therapies ineffective, leaving many patients with limited choices. The SPARK Trial aims to address this urgent need for new treatment strategies by exploring how Sitravatinib, an oral drug inhibiting multiple receptor tyrosine kinases, can enhance the anti-tumor effects of Tislelizumab, a potent PD-1 inhibitor.

The rationale behind this combination rests on their distinct yet complementary mechanisms of action. Sitravatinib targets tumor microenvironment signaling pathways often exploited by cancer cells, while Tislelizumab aims to amplify the immune response against the tumor. By synergizing these effects, researchers anticipate a dual assault on the cancer cells, potentially resulting in improved patient outcomes. The preliminary findings of the trial show encouraging signs of efficacy, with notable response rates among participants.

One of the standout features of the SPARK Trial is its multi-cohort design, which allows for a more comprehensive assessment of patient response across various demographics and disease stages. This approach provides insights not only into the treatment’s overall effectiveness but also its applicability to diverse patient populations, making it a crucial piece of evidence in the fight against TNBC. The trial’s results could pave the way for broader clinical applications, giving hope to those who have historically faced poor prognoses.

As patients enrolled in the study undergo treatment, their responses are meticulously documented, providing a rich data pool from which researchers can draw conclusions. The study emphasizes the importance of real-world data in understanding how treatments perform outside controlled clinical settings. Such insights are vital as they inform future research directions and treatment protocols in oncology.

Moreover, the combination therapy approach aligns with the growing trend towards personalized medicine, where treatments are tailored to an individual’s unique cancer profile. By assessing the tumor’s specific characteristics and the patient’s overall health, oncologists can devise more effective strategies, minimizing the trial-and-error approach that often accompanies cancer treatment. The SPARK Trial exemplifies this shift, demonstrating how targeted therapies can be combined strategically to enhance patient outcomes.

In the realm of metastatic breast cancer, where the disease has spread beyond the primary tumor site, the stakes are particularly high. The burden of metastasis often signifies a shift to advanced disease, with a corresponding decline in treatment options. Thus, any new avenues to treat these patients are of paramount importance. The SPARK Trial seeks to redefine the treatment landscape, offering hope that a combination of Sitravatinib and Tislelizumab may translate into longer survival times and improved quality of life for this vulnerable population.

Exploring the safety profile of the combined therapies is another essential aspect of the trial. While the promise of efficacy is paramount, the tolerability of treatments greatly influences patient adherence and overall outcomes. Researchers closely monitor adverse effects, striving to strike a balance between therapeutic benefits and potential risks. Early feedback from trial participants suggests that the Sitravatinib and Tislelizumab combination is well-tolerated, a crucial finding that will be pivotal as the trial progresses.

The SPARK Trial not only sheds light on the potential benefits of dual therapy but also emphasizes the role of collaboration across research institutions and pharmaceutical companies. This multifaceted approach brings together expertise from various sectors to tackle the complex challenges presented by aggressive cancer types. Such collaborations are essential for fostering innovation, accelerating the translation of research findings from the laboratory to the clinic.

In summation, the exploration of Sitravatinib in combination with Tislelizumab within the SPARK Trial represents a beacon of hope for those battling locally recurrent or metastatic triple-negative breast cancer. The positive preliminary results serve as a compelling argument for continued investment in research and development in this critical area. As the clinical trial unfolds, further analysis will be required to assess long-term outcomes and potential for standardization of this therapy.

This study not only contributes to the existing body of knowledge surrounding TNBC treatments but also underscores the importance of exploring novel drug combinations in oncology. As cancer research continues to advance, the lessons drawn from trials such as SPARK may well inform future directions, reshaping the therapeutic landscape and ultimately improving survival rates for patients facing this formidable disease. The future of cancer treatment lies in understanding the specific biology of tumors and devising effective strategies that capitalize on these insights. Thus, the SPARK Trial stands as a glimmer of optimism on the horizon of cancer therapy evolution.

In the years to come, it’s essential that researchers closely monitor the results from this trial to determine its full impact on clinical practice. The potential to improve patient outcomes significantly can transform the landscape for many individuals facing grim prognoses with triple-negative breast cancer. As we await further updates, the medical community remains hopeful for groundbreaking advancements driven by impactful research initiatives such as the SPARK Trial.

Understanding the implications of Sitravatinib and Tislelizumab in treating advanced breast cancer could revolutionize the way oncologists approach personalized treatment plans. Increased awareness and data dissemination from this trial will likely inspire further research, ultimately leading to enhanced care strategies and, hopefully, improved survival rates for patients in desperate need of effective therapies.

The SPARK Trial exemplifies the power of clinical research to transcend the limitations of existing treatment modalities and offer renewed hope to patients. As we look to the future, it is critical that the findings of this study are shared widely so that the insights gained can inform ongoing research efforts and ultimately improve lives across the globe. This is the essence of scientific inquiry and the relentless pursuit of better outcomes for those affected by cancer.

In an arena where breakthroughs can transform the course of treatment for millions, the SPARK Trial shines brightly as a testament to the potential of innovative combination therapies. The research landscape is ever-evolving, and with diligent efforts, we may soon witness a new chapter in the battle against triple-negative breast cancer, driven by comprehensive studies like this one.

As we progress, continued collaborative efforts in the field oncology will be paramount. Through shared knowledge, pooled resources, and a joint commitment to patient welfare, the journey towards effective cancer treatments will undoubtedly gain momentum. It is these very initiatives that forge advancements in medical science and bring forth the possibility of a future where cancer is not just managed, but more effectively treated, ultimately leading to better quality of life for patients everywhere.

Subject of Research: Combination therapy using Sitravatinib and Tislelizumab for triple-negative breast cancer.

Article Title: Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).

Article References:

Liu, XY., Sui, XY., Xu, Y. et al. Sitravatinib plus tislelizumab in locally recurrent or metastatic triple-negative breast cancer: a multi-cohort, single-arm, phase II clinical trial (SPARK Trial).
Mol Cancer 25, 15 (2026). https://doi.org/10.1186/s12943-025-02505-5

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12943-025-02505-5

Keywords: triple-negative breast cancer, Sitravatinib, Tislelizumab, immunotherapy, combination therapy, SPARK Trial.